The vaccine, codenamed BNT162b5, codes for “enhanced” prefusion spike proteins from the original wild-type strain of the virus and the Omicron variant that are designed to increase “the magnitude and breadth of the immune response.”
The phase 2 trial will test a 30 µg dose of the shot in around 200 adult volunteers in the US who have already received one booster dose at least 90 days before enrolment, said Pfizer. Subjects in the study will be separated into different groups, depending on the number of months since their first booster.